About Us
About us
Transforming GI tissue regeneration
Curileum Discovery Ltd is a biotechnology company based adjacent to St Mark’s Hospital in London, one of the world’s only gastrointestinal (GI)-dedicated hospitals. Backed by over 40 years of drug discovery, we focus on developing novel therapies that restore the health of GI tissues, intervening early in disease development to prevent bowel cancer and treat inflammatory bowel disease (IBD).
Bowel cancer is the second leading cause of cancer deaths worldwide, costing the NHS over £1 billion annually1 in the UK (for all management, treatment and follow-ups). An estimated 20% of colonoscopies2 are performed as part of surveillance programmes, highlighting a substantial opportunity to reduce resource use through changes to monitoring and treatment.
Our team has discovered and is developing a novel, oral, small molecule drug – ULI262 – that addresses the root cause of bowel cancer: abnormal cell production driving polyp formation.
We have also identified a new source of multipotent adult stem cells in the lower part of the gut for regenerative medicine. ATZ stem cells could offer the first curative treatment for perianal fistulas in Crohn’s patients, as well as treatment potential for a wide range of other diseases.
Curileum is guided by an experienced team of scientific and clinical advisors. Our founder and CEO, Dr Jeff Moore, has worked at the forefront of research into the regulation of cell production throughout his career. Dr Moore previously led the discovery and development of a novel protein that protected the bone marrow and GI tract from the toxicity of chemotherapy, including raising over $20m.
We are raising £5m for a first-in-human clinical study in FAP patients starting in 2026. The company’s drug development team, supported by its scientific and clinical advisory boards, is on track to optimise ULI262’s chemical synthesis, scale up drug production, complete preclinical pharmacology and toxicity studies, and prepare regulatory documentation for a Clinical Trial Application. We expect the FDA will grant Orphan drug designation for the treatment of FAP, helping to expedite the clinical trial process and accelerate the timeline to treating patients in urgent need.
Please contact us to discuss potential investment opportunities.
1 https://www.ncbi.nlm.nih.gov/books/NBK580741/
2 https://www.ncbi.nlm.nih.gov/books/NBK580741/
